Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Analysis of therapeutic effect and prognosis in patients with metastatic colorectal cancer and different K-ras status].

Zhonghua zhong liu za zhi [Chinese journal of oncology] - 1 Apr 2013

Ge Fei-jiao, Liu Jian-zhi, Li Shan-shan, Wang Yan, Liu Lie-jun, Yao Kai, Zhao Chuan-hua, Fu Ya-Li, Lin Li, Xu Jian-ming

Abstract excerpt

OBJECTIVE: To evaluate the correlation of clinical effect and prognosis between patients with metastatic colorectal cancer (mCRC) and different K-ras status. METHODS: The clinical characteristics, chemotherapeutic regimens and survival of 153 mCRC patients with different K-ras status were analyzed retrospectively. RESULTS: The median overall survival (OS) in patients without K-ras mutation were 31.7 months,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Phytogenic
Share to Camptothecin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Combined Modality Therapy

Share to Disease-Free Survival

Share to Genes, ras

Share to Irinotecan

Share to Organoplatinum Compounds

Share to Oxaliplatin

Source

Identifiers

PMID: 23985255
DOI: 10.3760/cma.j.issn.0253-3766.2013.04.007

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Analysis of therapeutic effect and prognosis in patients with metastatic colorectal cancer and different K-ras status].PMID 23985255Read ↗

Association of RAS/BRAF Status and Prognosis of Metastatic Colorectal Cancer: Analysis of 1002 Consecutive Cases.Semantic proximity Read ↗

Detection of K-ras Mutations in Predicting Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase (EGFR-TK) Inhibitor in Patients with Metastatic Colorectal Cancer.Semantic proximity Read ↗

Cetuximab plus chemotherapy as first-line treatment for metastatic colorectal cancer: effect of KRAS mutation on treatment efficacy in Taiwanese patients.Semantic proximity Read ↗

The Real-Life Data of BRAF Mutation on the Treatment of Colorectal Cancer: a TOG Study.Semantic proximity Read ↗

[Clinical relevance of the K-ras oncogene in colorectal cancer: experience in a Mexican population].Semantic proximity Read ↗

[Cetuximab for patients with metastatic colorectal cancer-from the result of recent clinical trials].Semantic proximity Read ↗

Cetuximab versus bevacizumab in metastatic colorectal cancer: a comparative effectiveness study.Semantic proximity Read ↗

Cetuximab-based therapy for metastatic colorectal cancer: a meta-analysis of the effect of K-ras mutations.Semantic proximity Read ↗

Can K-ras gene mutation be utilized as prognostic biomarker for colorectal cancer patients receiving chemotherapy? A meta-analysis and systematic review.Semantic proximity Read ↗

KRAS and BRAF Mutations as survival prognostic factors for Metastatic Colorectal Cancer patients after Lung metastasectomy: A Systematic Review and Meta-AnalysisSemantic proximity Read ↗

A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer.Semantic proximity Read ↗

Efficacy of Oxaliplatin/5-Fluorouracil/Capecitabine-Cetuximab Combination Therapy and Its Effects on K-Ras Mutations in Advanced Colorectal Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.